Compare RIOT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIOT | RYTM |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.8B |
| IPO Year | 2002 | 2017 |
| Metric | RIOT | RYTM |
|---|---|---|
| Price | $15.84 | $81.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $25.43 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 16.3M | 601.3K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $647,435,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $24.12 | $86.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 71.89 | N/A |
| 52 Week Low | $7.40 | $55.31 |
| 52 Week High | $23.94 | $122.20 |
| Indicator | RIOT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 38.51 |
| Support Level | $12.02 | $74.50 |
| Resistance Level | $19.43 | $90.79 |
| Average True Range (ATR) | 1.08 | 3.25 |
| MACD | -0.12 | -0.12 |
| Stochastic Oscillator | 14.10 | 16.59 |
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.